Pürin ve Pirimidin Metabolizması Bozuklukları ve Görüntüleme Bulguları

Chitrakar I, Kim-Holzapfel DM, Zhou W, French JB. Higher order structures in purine and pyrimidine metabolism. J Struct Biol. 2017;197(3):354-364.

Balasubramaniam S, Duley JA, Christodoulou J. Inborn errors of purine metabolism: clinical update and therapies. J Inherit Metab Dis. 2014;37(5):669-86.

Marie S, van den Berghe G, Vincent F. (2022). Disorders of purine and pyrimidine metabolism. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Heidelberg: Springer, Berlin; p.587-609.

Tian R, Yang C, Chai SM, Guo H, Seim I, Yang G. Evolutionary impacts of purine metabolism genes on mammalian oxidative stress adaptation. Zool Res. 2022;43(2):241-254.

Zhao H, French JB, Fang Y, Benkovic SJ. The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans. Chem Commun (Camb). 2013;49(40):4444-52.

Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy. Front Immunol. 2018;9:1697.

Duran M, Dorland L, Meuleman EE, Allers P, Berger R. Inherited defects of purine and pyrimidine metabolism: laboratory methods for diagnosis. J Inherit Metab Dis. 1997;20(2):227-36.

Ng BG, Wolfe LA, Ichikawa M, et al. Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors. Hum Mol Genet. 2015;24(11):3050-7.

Balasubramaniam S, Duley JA, Christodoulou J. Inborn errors of pyrimidine metabolism: clinical update and therapy. J Inherit Metab Dis. 2014;37(5):687-98.

van Gennip AH, Abeling NG, Vreken P, van Kuilenburg AB. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis. 1997;20(2):203-13.

Dewulf JP, Marie S, Nassogne MC. Disorders of purine biosynthesis metabolism. Mol Genet Metab. 2022;136(3):190-198.

Baresova V, Krijt M, Skopova V, Souckova O, Kmoch S, Zikanova M. CRISPR-Cas9 induced mutations along de novo purine synthesis in HeLa cells result in accumulation of individual enzyme substrates and affect purinosome formation. Mol Genet Metab. 2016;119(3):270-277.

Jurecka A, Zikanova M, Kmoch S, Tylki-Szymańska A. Adenylosuccinate lyase deficiency. J Inherit Metab Dis. 2015;38(2):231-42.

Mouchegh K, Zikánová M, Hoffmann GF, et al. Lethal fetal and early neonatal presentation of adenylosuccinate lyase deficiency: observation of 6 patients in 4 families. J Pediatr. 2007;150(1):57-61.e2.

van Werkhoven MA, Duley JA, McGown I, Munce T, Freeman JL, Pitt JJ. Early diagnosis of adenylosuccinate lyase deficiency using a high-throughput screening method and a trial of oral S-adenosyl-l-methionine as a treatment method. Dev Med Child Neurol. 2013;55(11):1060-4.

Ramond F, Rio M, Héron B, et al, Touraine R. AICA-ribosiduria due to ATIC deficiency: Delineation of the phenotype with three novel cases, and long-term update on the first case. J Inherit Metab Dis. 2020;43(6):1254-1264.

Lee A, Knox R, Reynolds M, McRoy E, Nguyen H. S-adenosylmethionine and nicotinamide riboside therapy in Arts syndrome: A case report and literature review. JIMD Rep. 2023;64(6):417-423.

Akizu N, Cantagrel V, Schroth J, et al. AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder. Cell. 2013;154(3):505-17.

Kortüm F, Jamra RA, Alawi M, et al. Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. Eur J Hum Genet. 2018;26(5):695-708.

Jinnah HA, Ceballos-Picot I, Torres RJ, et al; Lesch-Nyhan Disease International Study Group. Attenuated variants of Lesch-Nyhan disease. Brain. 2010;133(Pt 3):671-89.

Fu R, Ceballos-Picot I, Torres RJ, et al; Lesch-Nyhan Disease International Study Group. Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain. 2014;137(Pt 5):1282-303.

Watts RW, McKeran RO, Brown E, Andrews TM, Griffiths MI. Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome. Arch Dis Child. 1974;49(9):693-702.

Chen BC, Balasubramaniam S, McGown IN, et al. Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl. Brain Dev. 2014;36(7):593-600.

Vijiaratnam N, Bhatia KP, Lang AE, Raskind WH, Espay AJ. ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. Mov Disord Clin Pract. 2019;6(7):512-520.

Méneret A, Gras D, McGovern E, Roze E. Caffeine and the Dyskinesia Related to Mutations in the ADCY5 Gene. Ann Intern Med. 2019;171(6):439.

Bowne SJ, Sullivan LS, Mortimer SE, et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006;47(1):34-42.

Kuukasjärvi A, Landoni JC, Kaukonen J, et al. IMPDH2: a new gene associated with dominant juvenile-onset dystonia-tremor disorder. Eur J Hum Genet. 2021;29(12):1833-1837.

Kevelam SH, Bierau J, Salvarinova R, et al. Recessive ITPA mutations cause an early infantile encephalopathy. Ann Neurol. 2015 Oct;78(4):649-58.

Ng BG, Wolfe LA, Ichikawa M, et al. Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors. Hum Mol Genet. 2015;24(11):3050-7.

Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010;42(1):30-5.

Duley JA, Henman MG, Carpenter KH, et al. Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine. Mol Genet Metab. 2016;119(1-2):83-90.

van Gennip AH, Abeling NG, Vreken P, van Kuilenburg AB. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis. 1997;20(2):203-13.

van Kuilenburg AB, Dobritzsch D, Meijer J, et al. Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta. 2010;1802(7-8):639-48.

van Kuilenburg AB, Dobritzsch D, Meijer J, et al. ß-ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta. 2012;1822(7):1096-108.

Page T, Yu A, Fontanesi J, Nyhan WL. Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A. 1997;94(21):11601-6.

de Brouwer APM, Christodoulou J. Phosphoribosylpyrophosphate Synthetase Superactivity. 2008 Sep 23 [updated 2022 Feb 17]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.

Becker MA, Puig JG, Mateos FA, Jimenez ML, Kim M, Simmonds HA. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988;85(3):383-90.

Yamamoto T, Moriwaki Y, Takahashi S, et al. Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II. Metabolism. 2003;52(11):1501-4.

Schwahn BC, Van Spronsen FJ, Belaidi AA, et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet. 2015;386(10007):1955-1963.

Edvardsson VO, Sahota A, Palsson R. Adenine Phosphoribosyltransferase Deficiency. 2012 Aug 30 [updated 2019 Sep 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.

Runolfsdottir HL, Palsson R, Thorsteinsdottir UA, et al. Urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency, carriers and healthy control subjects. Mol Genet Metab. 2019;128(1-2):144-150.

Nakayama A, Matsuo H, Ohtahara A, et al. Clinical practice guideline for renal hypouricemia (1st edition). Hum Cell. 2019;32(2):83-87.

Devuyst O, Olinger E, Weber S, et al. Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers. 2019;5(1):60.

Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol. 1998;35(4):291-8.

South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. Pharmacoecon Open. 2019;3(2):151-161.

Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911-20.

Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018;38(5):569-578.

Fekrvand S, Yazdani R, Abolhassani H, Ghaffari J, Aghamohammadi A. The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA Deficiency and a Review of the Literature. Immunol Invest. 2019;48(4):410-430.

Niizuma H, Kanno H, Sato A, Ogura H, Imaizumi M. Splenectomy resolves hemolytic anemia caused by adenylate kinase deficiency. Pediatr Int. 2017;59(2):228-230.

Suchi M, Mizuno H, Kawai Y, et al. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet. 1997;60(3):525-39.

Bogusławska DM, Skulski M, Bartoszewski R, et al. A rare mutation (p.F149del) of the NT5C3A gene is associated with pyrimidine 5'-nucleotidase deficiency. Cell Mol Biol Lett. 2022;27(1):104.

Bogusławska DM, Skulski M, Bartoszewski R, et al. A rare mutation (p.F149del) of the NT5C3A gene is associated with pyrimidine 5'-nucleotidase deficiency. Cell Mol Biol Lett. 2022;27(1):104.

Park HJ, Hong JM, Lee JH, et al. Comparative transcriptome analysis of skeletal muscle in ADSSL1 myopathy. Neuromuscul Disord. 2019;29(4):274-281.

Mroczek M, Durmus H, Bijarnia-Mahay S, et al. Expanding the disease phenotype of ADSSL1-associated myopathy in non-Korean patients. Neuromuscul Disord. 2020;30(4):310-314.

Staufner C, Lindner M, Dionisi-Vici C, et al. Adenosine kinase deficiency: expanding the clinical spectrum and evaluating therapeutic options. J Inherit Metab Dis. 2016;39(2):273-83.

El-Hattab AW, Scaglia F. Deoxyguanosine Kinase Deficiency. 2009 Jun 18 [updated 2023 Feb 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.

Keshavan N, Abdenur J, Anderson G, et al. The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency. Genet Med. 2020;22(1):199-209.

Ceballos F, Serrano-Lorenzo P, Bermejo-Guerrero L, Blázquez A, Quesada-Espinosa JF, Amigo J, Minguez P, Ayuso C, García-Arumí E, Muelas N, Jaijo T, Nascimento A, Galán-Rodriguez B, Paradas C, Arenas J, Carracedo A, Martí R, Martín MA, Domínguez-González C; for TK2d Spanish-Group. Clinical and Genetic Analysis of Patients With TK2 Deficiency. Neurol Genet. 2024;10(2):e200138.

Dominguez-Gonzalez C, Badosa C, Madruga-Garrido M, et al. Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy. Sci Rep. 2020;10(1):10111.

Nishino I, Spinazzola A, Papadimitriou A, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol. 2000;47(6):792-800.

Tamm R, Oselin K, Kallassalu K, et al. Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clin Chem Lab Med. 2008;46(7):974-9.

Gupta N, Magatha LS, Jayaraman D, Scott JX, Antony SB, Koshy T. Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant. J Oncol Pharm Pract. 2023;29(4):999-1001.

Yin D, Xia X, Zhang J, et al. Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. Oncotarget. 2017;8(8):13575-13585.

Lešnjaković L, Ganoci L, Bilić I, et al. DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics. 2023;24(2):93-106.

Ding X, Chen W, Fan H, Zhu B. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene. 2015;559(1):31-7.

van Gennip AH. Defects in metabolism of purines and pyrimidines. Ned Tijdschr Klin Chem 1999; 24: 171-175.

Jurecka A, Tylki-Szymanska A. Inborn errors of purine and pyrimidine metabolism: A guide to diagnosis. Mol Genet Metab. 2022;136(3):164-176.

Al Orf A, Waheed KB, Ali EM, et al. Inherited paediatric neurometabolic disorders, can brain magnetic resonance imaging predict? Neurosciences (Riyadh). 2020;25(5):392-398.

Jurecka A. Inborn errors of purine and pyrimidine metabolism. J Inherit Metab Dis. 2009;32(2):247-63.

Ho ML, Rojas R, Eisenberg RL. Cerebral edema. AJR Am J Roentgenol. 2012;199(3):W258-73.

Normal myelination | Radiology Reference Article | Radiopaedia.org